FOXO4 10mg

Descripción

About FOXO4 10mg

What is FOXO4-DRI?
Senescent cells — the ones that have stopped dividing but refuse to die — stay alive by sequestering p53 in the nucleus through a FOXO4-p53 interaction. FOXO4-DRI disrupts that interaction. When the partnership breaks, p53 is free to do what it normally does in damaged cells: trigger apoptosis. The senescent cell dies. The healthy cell next door, which does not depend on FOXO4-p53 for survival, is unaffected.

Peter de Keizer at Erasmus University published this mechanism in 2017. It was the first peptide-based senolytic — a compound that selectively kills senescent cells.

Mechanism of Action

The D-retro-inverso trick
DRI stands for D-retro-inverso. All the amino acids are D-form (mirror image of natural L-amino acids) and the sequence runs backwards. This makes the peptide invisible to proteases — enzymes that normally chop up peptides cannot recognize D-amino acid substrates. So FOXO4-DRI has the binding specificity of the natural FOXO4 sequence but the metabolic stability that natural peptides lack.

Mechanism
Competes with endogenous FOXO4 for p53 binding. In senescent cells, FOXO4 keeps p53 trapped in the nucleus and away from the mitochondria where it would trigger apoptosis. FOXO4-DRI outcompetes this interaction, releasing p53. Free p53 translocates to mitochondria and initiates the intrinsic apoptosis pathway. Only cells that depend on FOXO4-p53 for survival are affected — which is specifically senescent cells.

Research Overview

Almacenamiento
Lyophilized at -20°C. Reconstituted: 2-8°C, use within 4 weeks.

Calidad
Class-level specification ≥98%. Sold and shipped from the EU by CERTALAB S.R.L.

Product Specifications

• Molecular weight: ~5,500 Da
• Purity: ≥98% (class-level specification)
• Forma: Lyophilized powder
• SKU: CP-F410

Independent reports, where on record, are searchable by batch or report code. View reports →

Solo para fines de investigación. No apto para el consumo humano.